4 news items
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEVA
1 Jun 24
antipsychotics, may cause somnolence and has the potential to impair judgement, thinking, and motor skills. Somnolence was a commonly reported adverse
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
TEVA
15 May 24
, including our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully compete in the marketplace, including
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
TEVA
8 May 24
to attract, hire, integrate and retain highly skilled personnel; interruptions in our supply chain or problems with internal or third party manufacturing
New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024
TEVA
6 Apr 24
: UZEDY, like other antipsychotics, may cause somnolence and has the potential to impair judgement, thinking, and motor skills. Somnolence
- Prev
- 1
- Next